Muscle wasting and impaired Myogenesis in tumor bearing mice are prevented by ERK inhibition

PLoS ONE

Volumn 5, Issue 10, 2010, Pages

  Penna, Fabio ^a   Costamagna, Domiziana ^a   Fanzani, Alessandro ^b   Bonelli, Gabriella ^a   Baccino, Francesco M ^a   Costelli, Paola ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ATROGIN 1; MITOGEN ACTIVATED PROTEIN KINASE; MYOD PROTEIN; MYOGENIN; MYOSIN HEAVY CHAIN; TRANSCRIPTION FACTOR PAX7; TUMOR NECROSIS FACTOR ALPHA; FLAVONOID; PROTEIN KINASE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CACHEXIA; COLON ADENOCARCINOMA; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; MALE; MOUSE; MUSCLE ATROPHY; MUSCLE DEVELOPMENT; MUSCLE MASS; MUSCLE WEAKNESS; MYOBLAST; MYOTUBE; NONHUMAN; PROTEIN CONTENT; PROTEIN EXPRESSION; PROTEIN TARGETING; RAT; WEIGHT REDUCTION; ANIMAL; BAGG ALBINO MOUSE; BODY WEIGHT; CELL LINE; DRUG ANTAGONISM; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL NEOPLASM; FLUORESCENT ANTIBODY TECHNIQUE; ORGAN SIZE; PATHOLOGY; SKELETAL MUSCLE; WESTERN BLOTTING; WISTAR RAT;

MUS;

ANIMALS; BLOTTING, WESTERN; BODY WEIGHT; CELL LINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FLAVONOIDS; FLUORESCENT ANTIBODY TECHNIQUE; MALE; MICE; MICE, INBRED BALB C; MUSCLE, SKELETAL; MUSCULAR ATROPHY; NEOPLASMS, EXPERIMENTAL; ORGAN SIZE; PROTEIN KINASE INHIBITORS; RATS; RATS, WISTAR;

EID: 78149425900     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0013604     Document Type: Article

References (54)

1. Acharyya S, Guttridge DC (2007) Cancer cachexia signaling pathways continue to emerge yet much still points to the proteasome. Clin Cancer Res 13: 1356-1361.
2. Hasselgren PO, Wray C, Mammen J (2002) Molecular regulation of muscle cachexia: it may be more than the proteasome. Biochem Biophys Res Commun 290: 1-10.
3. Mammucari C, Milan G, Romanello V, Masiero E, Rudolf R, et al. (2007) FoxO3 controls autophagy in skeletal muscle in vivo. Cell Metab 6: 458-471.
4. Lecker SH, Jagoe RT, Gilbert A, Gomes M, Baracos V, et al. (2004) Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J 18: 39-51.
5. Guttridge DC, Mayo MW, Madrid LV, Wang CY, Baldwin AS Jr. (2000) NFkappaB- induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. Science 289: 2363-2366.
6. Glass DJ (2005) Skeletal muscle hypertrophy and atrophy signaling pathways. Int J Biochem Cell Biol 37: 1974-1984.
7. Penna F, Bonetto A, Muscaritoli M, Costamagna D, Minero VG, et al. (2009) Muscle atrophy in experimental cancer cachexia: Is the IGF-1 signaling pathway involved? Int J Cancer.
8. Raman M, Chen W, Cobb MH (2007) Differential regulation and properties of MAPKs. Oncogene 26: 3100-3112.
9. Keren A, Tamir Y, Bengal E (2006) The p38 MAPK signaling pathway: a major regulator of skeletal muscle development. Mol Cell Endocrinol 252: 224-230.
10. Puri PL, Wu Z, Zhang P, Wood LD, Bhakta KS, et al. (2000) Induction of terminal differentiation by constitutive activation of p38 MAP kinase in human rhabdomyosarcoma cells. Genes Dev 14: 574-584.
11. Miyake T, Alli NS, Aziz A, Knudson J, Fernando P, et al. (2009) Cardiotrophin- 1 maintains the undifferentiated state in skeletal myoblasts. J Biol Chem 284: 19679-19693.
12. Shi H, Zeng C, Ricome A, Hannon KM, Grant AL, et al. (2007) Extracellular signal-regulated kinase pathway is differentially involved in beta-agonist-induced hypertrophy in slow and fast muscles. Am J Physiol Cell Physiol 292: C1681-1689.
13. Shi H, Scheffler JM, Pleitner JM, Zeng C, Park S, et al. (2008) Modulation of skeletal muscle fiber type by mitogen-activated protein kinase signaling. FASEB J 22: 2990-3000.
14. Murgia M, Serrano AL, Calabria E, Pallafacchina G, Lomo T, et al. (2000) Ras is involved in nerve-activity-dependent regulation of muscle genes. Nat Cell Biol 2: 142-147.
15. Bonetto A, Penna F, Minero VG, Reffo P, Bonelli G, et al. (2009) Deacetylase inhibitors modulate the myostatin/follistatin axis without improving cachexia in tumor-bearing mice. Curr Cancer Drug Targets 9: 608-616.
16. Rommel C, Clarke BA, Zimmermann S, Nunez L, Rossman R, et al. (1999) Differentiation stage-specific inhibition of the Raf-MEK-ERK pathway by Akt. Science 286: 1738-1741.
17. Haddad F, Adams GR (2004) Inhibition of MAP/ERK kinase prevents IGF-Iinduced hypertrophy in rat muscles. J Appl Physiol 96: 203-210.
18. Strassmann G, Fong M, Kenney JS, Jacob CO (1992) Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J Clin Invest 89: 1681-1684.
19. Mitchell PO, Pavlath GK (2004) Skeletal muscle atrophy leads to loss and dysfunction of muscle precursor cells. Am J Physiol Cell Physiol 287: C1753-1762.
20. Costelli P, Muscaritoli M, Bossola M, Moore-Carrasco R, Crepaldi S, et al. (2005) Skeletal muscle wasting in tumor-bearing rats is associated with MyoD down-regulation. Int J Oncol 26: 1663-1668.
21. Alapat DV, Chaudhry T, Ardakany-Taghavi R, Kohtz DS (2009) Fiber-types of sarcomeric proteins expressed in cultured myogenic cells are modulated by the dose of myogenin activity. Cell Signal 21: 128-135.
22. Shi H, Scheffler JM, Zeng C, Pleitner JM, Hannon KM, et al. (2009) Mitogenactivated protein kinase signaling is necessary for the maintenance of skeletal muscle mass. Am J Physiol Cell Physiol 296: C1040-1048.
23. Carlson ME, Suetta C, Conboy MJ, Aagaard P, Mackey A, et al. (2009) Molecular aging and rejuvenation of human muscle stem cells. EMBO Mol Med 1: 381-391.
24. Yang SY, Hoy M, Fuller B, Sales KM, Seifalian AM, et al. Pretreatment with insulin-like growth factor I protects skeletal muscle cells against oxidative damage via PI3K/Akt and ERK1/2 MAPK pathways. Lab Invest 90: 391-401.
25. Kato K, Ito H, Kamei K, Iwamoto I, Inaguma Y (2002) Innervation-dependent phosphorylation and accumulation of alphaB-crystallin and Hsp27 as insoluble complexes in disused muscle. FASEB J 16: 1432-1434.
26. Hemdan DI, Hirasaka K, Nakao R, Kohno S, Kagawa S, et al. (2009) Polyphenols prevent clinorotation-induced expression of atrogenes in mouse C2C12 skeletal myotubes. J Med Invest 56: 26-32.
27. Li YP, Chen Y, John J, Moylan J, Jin B, et al. (2005) TNF-alpha acts via p38 MAPK to stimulate expression of the ubiquitin ligase atrogin1/MAFbx in skeletal muscle. FASEB J 19: 362-370.
28. Marinovic AC, Zheng B, Mitch WE, Price SR (2002) Ubiquitin (UbC) expression in muscle cells is increased by glucocorticoids through a mechanism involving Sp1 and MEK1. J Biol Chem 277: 16673-16681.
29. Costelli P, Muscaritoli M, Bonetto A, Penna F, Reffo P, et al. (2008) Muscle myostatin signalling is enhanced in experimental cancer cachexia. Eur J Clin Invest 38: 531-538.
30. Liu CM, Yang Z, Liu CW, Wang R, Tien P, et al. (2008) Myostatin antisense RNA-mediated muscle growth in normal and cancer cachexia mice. Gene Ther 15: 155-160.
31. Lenk K, Schur R, Linke A, Erbs S, Matsumoto Y, et al. (2009) Impact of exercise training on myostatin expression in the myocardium and skeletal muscle in a chronic heart failure model. Eur J Heart Fail 11: 342-348.
32. Yang W, Chen Y, Zhang Y, Wang X, Yang N, et al. (2006) Extracellular signalregulated kinase 1/2 mitogen-activated protein kinase pathway is involved in myostatin-regulated differentiation repression. Cancer Res 66: 1320-1326.
33. Bonetto A, Penna F, Minero VG, Reffo P, Costamagna D, et al. Glutamine prevents myostatin hyperexpression and protein hypercatabolism induced in C2C12 myotubes by tumor necrosis factor-alpha. Amino Acids.
34. Coolican SA, Samuel DS, Ewton DZ, McWade FJ, Florini JR (1997) The mitogenic and myogenic actions of insulin-like growth factors utilize distinct signaling pathways. J Biol Chem 272: 6653-6662.
35. Samuel DS, Ewton DZ, Coolican SA, Petley TD, McWade FJ, et al. (1999) Raf- 1 activation stimulates proliferation and inhibits IGF-stimulated differentiation in L6A1 myoblasts. Horm Metab Res 31: 55-64.
36. Kumar A, Chaudhry I, Reid MB, Boriek AM (2002) Distinct signaling pathways are activated in response to mechanical stress applied axially and transversely to skeletal muscle fibers. J Biol Chem 277: 46493-46503.
37. Kornasio R, Riederer I, Butler-Browne G, Mouly V, Uni Z, et al. (2009) Betahydroxy- beta-methylbutyrate (HMB) stimulates myogenic cell proliferation, differentiation and survival via the MAPK/ERK and PI3K/Akt pathways. Biochim Biophys Acta 1793: 755-763.
38. Crepaldi T, Bersani F, Scuoppo C, Accornero P, Prunotto C, et al. (2007) Conditional activation of MET in differentiated skeletal muscle induces atrophy. J Biol Chem 282: 6812-6822.
39. Bossola M, Muscaritoli M, Costelli P, Grieco G, Bonelli G, et al. (2003) Increased muscle proteasome activity correlates with disease severity in gastric cancer patients. Ann Surg 237: 384-389.
40. Trendelenburg AU, Meyer A, Rohner D, Boyle J, Hatakeyama S, et al. (2009) Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube size. Am J Physiol Cell Physiol 296: C1258-1270.
41. Morissette MR, Cook SA, Buranasombati C, Rosenberg MA, Rosenzweig A (2009) Myostatin inhibits IGF-I-induced myotube hypertrophy through Akt. Am J Physiol Cell Physiol 297: C1124-1132.
42. Moore-Carrasco R, Garcia-Martinez C, Busquets S, Ametller E, Barreiro E, et al. (2006) The AP-1/CJUN signaling cascade is involved in muscle differentiation: implications in muscle wasting during cancer cachexia. FEBS Lett 580: 691-696.
43. Halevy O, Piestun Y, Allouh MZ, Rosser BW, Rinkevich Y, et al. (2004) Pattern of Pax7 expression during myogenesis in the posthatch chicken establishes a model for satellite cell differentiation and renewal. Dev Dyn 231: 489-502.
44. Szalay K, Razga Z, Duda E (1997) TNF inhibits myogenesis and downregulates the expression of myogenic regulatory factors myoD and myogenin. Eur J Cell Biol 74: 391-398.
45. Coletti D, Moresi V, Adamo S, Molinaro M, Sassoon D (2005) Tumor necrosis factor-alpha gene transfer induces cachexia and inhibits muscle regeneration. Genesis 43: 120-128.
46. Nicolas N, Marazzi G, Kelley K, Sassoon D (2005) Embryonic deregulation of muscle stress signaling pathways leads to altered postnatal stem cell behavior and a failure in postnatal muscle growth. Dev Biol 281: 171-183.
47. Berardi E, Aulino P, Murfuni I, Toschi A, Padula F, et al. (2008) Skeletal muscle is enriched in hematopoietic stem cells and not inflammatory cells in cachectic mice. Neurol Res 30: 160-169.
48. Moresi V, Pristera A, Scicchitano BM, Molinaro M, Teodori L, et al. (2008) Tumor necrosis factor-alpha inhibition of skeletal muscle regeneration is mediated by a caspase-dependent stem cell response. Stem Cells 26: 997-1008.
49. Olguin HC, Olwin BB (2004) Pax-7 up-regulation inhibits myogenesis and cell cycle progression in satellite cells: a potential mechanism for self-renewal. Dev Biol 275: 375-388.
50. Ramamoorthy S, Donohue M, Buck M (2009) Decreased Jun-D and myogenin expression in muscle wasting of human cachexia. Am J Physiol Endocrinol Metab 297: E392-401.
51. Zhang L, Wang XH, Wang H, Du J, Mitch WE Satellite cell dysfunction and impaired IGF-1 signaling cause CKD-induced muscle atrophy. J Am Soc Nephrol 21: 419-427.
52. McFarlane C, Hennebry A, Thomas M, Plummer E, Ling N, et al. (2008) Myostatin signals through Pax7 to regulate satellite cell self-renewal. Exp Cell Res 314: 317-329.
53. Collins CA, Gnocchi VF, White RB, Boldrin L, Perez-Ruiz A, et al. (2009) Integrated functions of Pax3 and Pax7 in the regulation of proliferation, cell size and myogenic differentiation. PLoS One 4: e4475.
54. Acharyya S, Butchbach ME, Sahenk Z, Wang H, Saji M, et al. (2005) Dystrophin glycoprotein complex dysfunction: a regulatory link between muscular dystrophy and cancer cachexia. Cancer Cell 8: 421-432.